Association between potential drug interactions and clinical outcomes in hematopoietic stem cell transplantations

被引:3
作者
Valverde, Ingrid A. P. M. [1 ]
da Silva, Mario J. S. [1 ]
Retto, Maely P. F. [1 ]
机构
[1] Natl Canc Inst Jose Alencar Gomes da Silva, Multiprofess Residency Program, Rio De Janeiro, Brazil
关键词
Hematopoietic stem cell transplantation; pre-transplant conditioning; drug interactions; CYCLOSPORINE;
D O I
10.1177/1078155218775195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The association of anti-infective, antineoplastic and immunosuppressant drugs makes patients undergoing hematopoietic stem cell transplantation susceptible to the effects resulting from drug interactions. In this study, we analyzed the potential drug interactions in the association between anti-infective, antineoplastic and immunomodulators agents and their clinical effects presented by patients from a bone marrow transplant service of a Brazilian hospital specialized in cancer treatment. The retrospective cohort involved patients in the conditioning phase undergoing transplantation in the year 2013. The chi-square test was used to assess the association and the confidence interval considered was 95%. A total of 53 patients were included in the study and 69.8% (p=0.004) presented some potential drug interaction. Of these, 97.3% (p<0.001) exhibited some symptom that may be associated with these interactions. Interactions with cyclophosphamide and cyclosporine were the most serious effects. There has been a high frequency and variety of interactions that may impair the entire transplant process, putting the patient's life at risk. The potential interactions observed during the conditioning period were associated with the symptoms presented by the patients. Strategies are needed to minimize negative outcomes in transplant patients.
引用
收藏
页码:1105 / 1111
页数:7
相关论文
共 22 条
[1]  
ABRALE. AssociacAo Brasileira de Linfoma e Leucemia, 2011, TRANSPL CEL TRONC HE
[2]   Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients [J].
Alkan, Ali ;
Yasar, Arzu ;
Karci, Ebru ;
Koksoy, Elif Berna ;
Urun, Muslih ;
Senler, Filiz Cay ;
Urun, Yuksel ;
Tuncay, Gulseren ;
Ergun, Hakan ;
Akbulut, Hakan .
SUPPORTIVE CARE IN CANCER, 2017, 25 (01) :229-236
[3]   Drug-drug interactions in oncology: Why are they important and can they be minimized? [J].
Blower, P ;
de Wit, R ;
Goodin, S ;
Aapro, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (02) :117-142
[4]  
Corrêa Paulo M., 2016, Pharmacy Pract (Granada), V14, DOI 10.18549/PharmPract.2016.02.683
[5]  
Dana WJ, 2012, DRUG INFORM HDB 2012, P2387
[6]   Optimizing the use of cyclosporin in allogeneic stem cell transplantation [J].
Duncan, N. ;
Craddock, C. .
BONE MARROW TRANSPLANTATION, 2006, 38 (03) :169-174
[7]   Potential drug-drug interactions in hospitalised haematological patients [J].
Fernandez de Palencia Espinosa, Ma Angeles ;
Diaz Carrasco, Ma Sacramento ;
Sanchez Salinas, Andres ;
de la Rubia Nieto, Amelia ;
Espuny Miro, Alberto .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (06) :443-453
[8]   Drug interactions of anti-microbial agents used in hematopoietic stem cell transplantation [J].
Fonseca Guastaldi, Rosimeire Barbosa ;
Secoli, Silvia Regina .
REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2011, 19 (04) :960-967
[9]  
Fonseca RB, 2006, REV BRAS ONCOL CLIN, V3, P13
[10]   An update on the safety and interactions of antifungal drugs in stem cell transplant recipients [J].
Girmenia, Corrado ;
Iori, Anna Paola .
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) :329-339